StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen operating lease right-of-use assets ($M) ($M)

Form 10-K (DB)

Latest, FY2025
602
Period ended Dec 31, 2025
Change on a year earlier
+8.1%
557 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOperating lease right-of-use assets ($M) ($M)Year on yearSource
FY2025Dec 31, 2025602+8.1%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024557-14.4%Form 10-K (filed 2025-02-14) ↗
FY2023Dec 31, 2023651+12.4%Form 10-K (filed 2024-02-14) ↗
FY2022Dec 31, 2022579+2.3%Form 10-K (filed 2023-02-09) ↗
FY2021Dec 31, 2021566+38.7%Form 10-K (filed 2022-02-16) ↗
FY2020Dec 31, 2020408-13.0%Form 10-K (filed 2021-02-09) ↗
FY2019Dec 31, 2019469–Form 10-K (filed 2020-02-12) ↗

Cite this data

StockData. (2026). Amgen Operating lease right-of-use assets ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_rou

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.